Head-to-head · WeighScore
Belle Health vs Ondra Health
By GLP-1 ScorecardUpdated
Score comparison
Ondra Health has the higher recorded score — 86.8/100 to 73.8/100.
Ondra Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Ondra publishes monthly and prepaid compounded injection plans with pharmacy choices; compare the upfront bill, eligible pharmacy and early-cancellation repricing before choosing a term.
Before you choose
Before comparing the headline prices, the Belle Health review and the Ondra Health review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Belle Health vs Trimi and Big Easy Weight Loss vs Ondra Health compare each of them with another graded program, and the list of alternatives to Belle Health ranks the programs closest to Belle Health on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Belle Health | Ondra Health |
|---|---|---|
| WeighScore | 73.8/100 | 86.8/100 |
| Grade | C | B |
| Site position | #50 | #5 |
| Semaglutide | From $93/mo (compounded; supply terms unverified) | $149/mo (compounded; month-to-month) |
| Tirzepatide | From $179/mo (compounded; supply terms unverified) | $219/mo (compounded; month-to-month) |
| Coverage | All 50 states | Advertises 50 states; pharmacy and formulation eligibility varies |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #50 · C
FDAWarning letter issued to Belle Health LLC dba Belle in February 2026. See the FDA warning-letter database.
Strengths
- Weekly live group sessions with a named registered dietitian are included
- Provider review, nurse support, injection supplies and shipping are included
- Advertises the same price across dose levels
- Terms state telehealth availability in all 50 states
What to consider
- Starting prices do not establish the required supply length, upfront charge or renewal amount
- Compounded medications are not FDA-approved finished products
- Prescription products are nonrefundable after shipment; subscriptions may renew automatically
- FDA issued Belle Health LLC dba Belle a warning letter in February 2026; the letter is public in FDA's warning-letter database
Strengths
- Publishes monthly charges and separate upfront totals for longer plans
- Allows requests for an eligible pharmacy and formulation, subject to prescribing and availability
- Names independent clinical partners and advertises provider messaging, supplies and shipping
What to consider
- Six- and twelve-month plans require prepayment and an eligible Hallandale or Vials prescription
- Early prepaid cancellation reprices each three-month supply already sent at the regular quarterly rate
- Confirm the selected renewal cutoff and any earned consultation or administrative fees
- Branded and oral access, included lab testing and independent current certification were not established
Featured provider
Belle Health
Belle Health scores 73.8/100 (C). Belle offers compounded GLP-1 injections with clinician oversight, nurse support and weekly group dietitian sessions; confirm the supply commitment behind its starting prices.
Commercial relationships affect this placement. The score comparison above is separate.
FDAWarning letter issued to Belle Health LLC dba Belle in February 2026. See the FDA warning-letter database.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.